Antiviral treatment of chronic hepatitis B virus (HBV) infections.
Article Details
- CitationCopy to clipboard
De Clercq E, Ferir G, Kaptein S, Neyts J
Antiviral treatment of chronic hepatitis B virus (HBV) infections.
Viruses. 2010 Jun;2(6):1279-305. doi: 10.3390/v2061279. Epub 2010 May 31.
- PubMed ID
- 21994680 [ View in PubMed]
- Abstract
While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Tenofovir disoproxil DNA polymerase/reverse transcriptase Protein HBV-D UnknownInhibitorDetails